Related Experiment Video
Updated: Jun 5, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Fungal infections in transplant and oncology patients
Anna K Person1, Dimitrios P Kontoyiannis, Barbara D Alexander
1Division of Infectious Diseases, Department of Medicine, Duke University Health System, Duke University School of Medicine, Durham, NC 27710, USA. perso006@mc.duke.edu
Abstract:
Recent shifts in the epidemiology of invasive fungal infections (IFIs) among transplant and oncology populations have led to new recommendations on treatment; however, they have also brought new controversies. New pharmacologic therapies are being studied and guidelines for management of several IFIs have been changed accordingly. More information is being discovered about unique genetic factors that put some transplant recipients at greater risk than others for fungal infection. The role of immunomodulation continues to be investigated, and the delicate balance of maintaining some immune integrity while assuring protection of the graft remains critical. For transplant and oncology patients, the diagnosis and management of IFIs remain challenging, and improving outcomes depends on continued progress in all of these arenas. This article highlights recent advances and important factors to consider when treating transplant and oncology patients with IFIs.
Insights
Recent shifts in invasive fungal infections (IFIs) epidemiology necessitate updated treatment guidelines for transplant and oncology patients. Continued research into genetics and immunomodulation is crucial for improving patient outcomes and managing these challenging infections.
Area of Science:
- Infectious Diseases
- Transplant Medicine
- Oncology
Background:
- Shifting epidemiology of invasive fungal infections (IFIs) in transplant and oncology patients.
- Emergence of new controversies and treatment recommendations for IFIs.
- Increasing understanding of genetic predispositions to fungal infections in transplant recipients.
Purpose of the Study:
- To highlight recent advances in the diagnosis and management of IFIs.
- To discuss important factors influencing treatment strategies for IFIs in immunocompromised populations.
- To address the complexities of IFIs in transplant and oncology care.
Main Methods:
- Review of current literature on IFIs in transplant and oncology.
- Analysis of new pharmacologic therapies and updated management guidelines.
- Investigation into genetic factors and immunomodulation's role in IFIs.
Main Results:
- New pharmacologic therapies are under investigation.
- Guidelines for IFIs management have been revised.
- Genetic factors and immunomodulation significantly impact IFI risk and management.
Conclusions:
- Diagnosis and management of IFIs in transplant and oncology patients remain challenging.
- Improving outcomes requires continued progress in understanding IFIs.
- Balancing immune integrity and graft protection is critical in managing IFIs.
Related Concept Videos
Cryptococcal Meningitis
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Kidney Transplant III: Nursing Management
Antifungal Agents
